<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583869</url>
  </required_header>
  <id_info>
    <org_study_id>F061204006</org_study_id>
    <nct_id>NCT00583869</nct_id>
  </id_info>
  <brief_title>Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients</brief_title>
  <acronym>LYRICA</acronym>
  <official_title>The Role of Pregabalin in the Treatment of Post-Operative Pain in Fracture Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, prospective, double-blind pilot study designed to evaluate the
      potential effectiveness of pregabalin in post-operative pain management for patients who have
      sustained a fracture.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On admission, all patients who have sustained orthopaedic injuries of any type, including
      pelvis, will be screened. However, only those patients who will undergo a single episode of
      surgery during this hospitalization to surgically repair only one of their orthopaedic
      fractures will be interviewed by a clinical research nurse. If the patient meets all criteria
      for inclusion/exclusion in the study, the attending physician will consent the patient for
      inclusion in the study. Upon enrollment into the study, the clinical research nurse will
      obtain a thorough history from the patient concerning prior narcotic use, response to painful
      events in the past and will record details of the injury. Prior to surgery, the patient will
      be treated with narcotic pain medication as required in the judgment of the attending
      physician. The patient will then be randomized before surgery into a placebo group or
      pregabalin group. The attending physician will be blinded as to which study arm the patient
      is in.

      Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed
      on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the
      patients will be switched to oral oxycodone as needed with supplementation with IV Demerol
      for breakthrough pain. In addition, patients will receive either pregabalin 75mg orally (PO)
      BID, pregabalin 150mg PO BID or placebo beginning on the day of surgery until discharge.

      The clinical research nurse will complete a form which records the daily use of each of the
      post-operative pain medications. She will also ask the patient to complete a Visual Analog
      Scale (VAS) to assess pain each day while in the hospital.

      Upon discharge, the patient will be given study medication (pregabalin, 75mg PO BID, 150mg PO
      BID or placebo). Rescue medications will be allowed during the study (including
      post-operative and outpatient periods). Outpatient rescue medications will consist of
      hydrocodone/acetamenophen (APAP) 7.5mg PO every sic hours (Q6H) as needed (PRN). Patients
      will be followed for three months as an outpatient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of pain medication in morphine equivalent units used during the hospitalization.</measure>
    <time_frame>Screening - 5 - 15 minutes; Consent - 5-15 minutes; Follow-up - three 15-30-minute visits</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome measures will include Visual Analog Score, timing and frequency of rescue medications, Short-Form 36 Health Survey scores, and adverse events.</measure>
    <time_frame>Three 15-30-minute visits after surgery to complete SF-36 and Visual Analog Score for Pain.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient to receive placebo beginning on the day of surgery until discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive 75mg PO BID pregabalin beginning on the day of surgery until discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive 150mg PO BID pregabalin beginning on the day of surgery until discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.
Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.
Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>LYRICA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.
Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>LYRICA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  fractures requiring operative treatment during a single operative episode

          -  Adult patients between the ages of 19 and 70

        Exclusion Criteria:

          -  prior medical history of narcotic abuse or narcotic use within 2 weeks of injury
             (except those given in hospital)

          -  contraindications to pregabalin or narcotic analgesics

          -  significant closed head injury

          -  psychiatric illness requiring medical treatment

          -  surgery for other injuries (splenectomy, etc)

          -  history of seizures requiring current anticonvulsant therapy

          -  inability or unwillingness to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Theiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Turan A, White PF, Karamanlioglu B, Memis D, Tasdogan M, Pamuk√ßu Z, Yavuz E. Gabapentin: an alternative to the cyclooxygenase-2 inhibitors for perioperative pain management. Anesth Analg. 2006 Jan;102(1):175-81.</citation>
    <PMID>16368826</PMID>
  </reference>
  <reference>
    <citation>Fischer HB, Simanski CJ. A procedure-specific systematic review and consensus recommendations for analgesia after total hip replacement. Anaesthesia. 2005 Dec;60(12):1189-202. Review.</citation>
    <PMID>16288617</PMID>
  </reference>
  <reference>
    <citation>Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006 Feb;6(1):108-13. Epub 2005 Dec 22. Review.</citation>
    <PMID>16376147</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>January 5, 2014</last_update_submitted>
  <last_update_submitted_qc>January 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-operative Pain</keyword>
  <keyword>Fracture Patients</keyword>
  <keyword>Pregabalin</keyword>
  <keyword>LYRICA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

